Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares saw an uptick in trading volume on Friday . 758,008 shares were traded during trading, an increase of 107% from the previous session's volume of 366,400 shares.The stock last traded at $17.30 and had previously closed at $16.82.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on ACRS. StockNews.com began coverage on Aclaris Therapeutics in a research note on Wednesday, October 12th. They set a "sell" rating for the company. BTIG Research began coverage on Aclaris Therapeutics in a research note on Thursday, October 6th. They set a "buy" rating and a $32.00 price objective for the company. Stifel Nicolaus began coverage on Aclaris Therapeutics in a report on Tuesday, December 13th. They set a "buy" rating and a $29.00 target price on the stock. SVB Leerink reiterated an "outperform" rating on shares of Aclaris Therapeutics in a report on Tuesday, November 8th. Finally, The Goldman Sachs Group began coverage on Aclaris Therapeutics in a report on Thursday, December 1st. They set a "buy" rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Aclaris Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $28.67.
Get
Aclaris Therapeutics alerts:
Aclaris Therapeutics Stock Performance
The company has a fifty day simple moving average of $16.26 and a two-hundred day simple moving average of $16.04.
Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last issued its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.09. The company had revenue of $19.02 million for the quarter, compared to analyst estimates of $1.61 million. Aclaris Therapeutics had a negative return on equity of 39.41% and a negative net
margin of 349.26%. On average, equities analysts predict that Aclaris Therapeutics, Inc. will post -1.39 EPS for the current year.
Insider Activity
In other news, insider Joseph Monahan sold 5,000 shares of the business's stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $15.88, for a total value of $79,400.00. Following the sale, the insider now directly owns 96,386 shares in the company, valued at $1,530,609.68. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total value of $381,250.00. Following the sale, the director now owns 1,220,763 shares of the company's stock, valued at $18,616,635.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $15.88, for a total value of $79,400.00. Following the completion of the sale, the insider now directly owns 96,386 shares in the company, valued at approximately $1,530,609.68. The disclosure for this sale can be found here. Corporate insiders own 6.70% of the company's stock.
Institutional Trading of Aclaris Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Strs Ohio increased its position in Aclaris Therapeutics by 82.9% during the fourth quarter. Strs Ohio now owns 36,400 shares of the biotechnology company's stock worth $573,000 after buying an additional 16,500 shares during the last quarter. Bank of New York Mellon Corp increased its position in Aclaris Therapeutics by 15.7% during the third quarter. Bank of New York Mellon Corp now owns 233,882 shares of the biotechnology company's stock worth $3,682,000 after buying an additional 31,683 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in Aclaris Therapeutics during the third quarter worth approximately $850,000. California State Teachers Retirement System increased its position in Aclaris Therapeutics by 5.8% during the third quarter. California State Teachers Retirement System now owns 65,616 shares of the biotechnology company's stock worth $1,033,000 after buying an additional 3,618 shares during the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in Aclaris Therapeutics during the third quarter worth approximately $1,670,000. Institutional investors and hedge funds own 95.33% of the company's stock.
Aclaris Therapeutics Company Profile
(Get Rating)
Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
See Also
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- PCE Indicates Slowdown In Spending, Economy Weakens
- Microsoft's Comeback Is Now Underway
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
